Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 274 Show results per page	View Search Criteria \| Help With Results

Last Modified: 9/20/2005


1.		Phase III Randomized Study of Topotecan vs Observation Following CDDP/VP-16 for Extensive Stage Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				NCI				ECOG-E7593 E7593

Last Modified: 11/1/1994


2.		Phase III Randomized, Open-Label, Multicenter Study of Topotecan vs Paclitaxel as Single-Agent, Second-Line Therapy for Platinum-Refractory Advanced Epithelial Ovarian Carcinoma (Summary Last Modified 11/94)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over								SB-104864/039 NCI-V94-0490

Last Modified: 6/1/1997


3.		Phase III Randomized Study of TOPO vs CAV (CTX/DOX/VCR) as Second-Line Therapy for Recurrent Small Cell Lung Cancer (Summary Last Modified 06/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				SB-104864/090 NCI-V95-0673

Last Modified: 6/1/1999


4.		Phase III, Randomized, Open-Label, Comparative Study of Liposomal Doxorubicin (DOXIL) versus Topotecan HCl in Patients with Epithelial Ovarian Carcinoma Following Failure of First Line, Platinum Based Chemotherapy (Summary Last Modified 06/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				SEQUUS-30-49 NCI-V97-1257

Last Modified: 5/31/2007 First Published: 8/1/1999


5.		Phase III Randomized Study of Oral Versus Intravenous Topotecan in Patients With Limited or Extensive Small Cell Lung Cancer That Has Relapsed Following First Line Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				CWRU-SKF-1598 SB-104864-A/396, NCI-G99-1524, NCT00003917

Last Modified: 7/10/2008 First Published: 8/1/1999


6.		Phase III Randomized Study of Cisplatin Only Versus Cisplatin Plus Topotecan Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Patients With Stage IVB, Recurrent, or Persistent Carcinoma of the Cervix

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				NCI				GOG-0179 ECOG-G0179, NCT00003945, GOG-0179

Last Modified: 10/3/2007 First Published: 8/1/1999


7.		Phase III Randomized Study of Vincristine, Dactinomycin, and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine, Topotecan, and Cyclophosphamide in Patients With Intermediate-Risk, Previously Untreated Rhabdomyosarcoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				Under 50				NCI				COG-D9803 CCG-D9803, POG-D9803, IRS-D9803, NCT00003958, D9803

Last Modified: 10/3/2007 First Published: 1/1/2000


8.		Phase III Randomized Study of Purged Versus Unpurged Peripheral Blood Stem Cell Transplantation After Dose-Intensive Induction Chemotherapy in Patients With Newly Diagnosed High Risk Neuroblastoma or Ganglioneuroblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				30 and under				NCI				COG-A3973 CCG-A3973, POG-A3973, CCG-39703, FHCRC-1631.00, NCT00004188, A3973

Last Modified: 6/12/2007 First Published: 11/1/2000


9.		Phase III Randomized Study of Paclitaxel and Carboplatin With or Without Topotecan in Patients With Stage IIB, III, or IV Ovarian Epithelial Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over								AGOSG-OVAR-7 NCI-V00-1602, NCT00006454

Last Modified: 8/19/2008 First Published: 3/1/2001


10.		Phase III Randomized Study of Paclitaxel and Carboplatin With or Without Gemcitabine, Doxorubicin HCl Liposome, or Topotecan in Patients With Stage III or IV Ovarian Epithelial or Serous Primary Peritoneal Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Any age				NCI				GOG-0182 SWOG-G0182, MRC-ICON5, ECOG-G0182, NCT00011986, GOG-0182

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute